Carolinas HealthCare System

Research and Clinical Trials

Lung 

Brief Description PrincipalĀ Investigator
The primary objective of this study is to evaluate the safety and tolerability of LY2835219 when administered orally in combination with multiple single-agent options to patients with Stage IV non-small cell lung cancer (NSCLC) using Common Terminology Criteria for Adverse Events (CTCAE version 4.0, NCI 2009). The secondary objectives of the study are to determine the pharmacokinetics (PK) of LY2835219 when given in combination with multiple single-agent options; to document the antitumor activ Kim, Edward 
To investigate the safety and tolerability of AZD9291 when given orally to patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have progressed following prior therapy with an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) agent. Secondary objectives include defining the maximum tolerated dose or maximum feasible dose of AZD9291; to investigate the safety and tolerability of AZD9291 when given orally as first line therapy to patients who Haggstrom, Daniel 
The purpose of this specimen banking study is to determine the positive predictive value (PPV) and negative predictive value (NPV) of the multi-protein classifier based on the observed prevalence of Non-Small Cell Lung Cancer, for patients with a lung nodule between 8 mm to 20 mm in size, except for those characterized as "pure ground glass opacity" or "non-solid." Mileham, Kathryn 
To evaluate the overall response rate (ORR) of LY2875358 plus Erlotinib Therapy and LY2875358 monotherapy in Patients with Met Proto-Oncogene (hepatocyte growth factor receptor)(MET) diagnostic positive (MET diagnostic (+)) non-small cell lung cancer (NSCLC) and acquired resistance to erlotinib. Mileham, Kathryn 
To compare the overall survival (OS) of previously treated patients with SCC NSCLC treated with MK-3475 compared to docetaxel. Carrizosa, Daniel 
The primary purpose of the study is to compare the antitumor activity of LDK378 versus chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib. Frenette, Gary 
To determine the maximum tolerated dose (MTD) of carfilzomib given in combination with standard dose carboplatin on Day 1 and etoposide on Days 1, 2, and 3 every 3 weeks as treatment for previously untreated extensive-stage small-cell lung cancer (ES-SCLC). Haggstrom, Daniel 
To compare overall survival in patients with stage IV or recurrent non-small cell lung cancer (NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (if appropriate) with or without cetuximab. Carrizosa, Daniel 
About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity and Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy Policy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.